CA
RCKT icon

Clearstead Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Clearstead Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419 Buy
+122
New +$406 ﹤0.01% 2976
2026
Q1 		– Sell
-14
Closed -$50 – 2725
2025
Q4 		$50 Sell
14
-712
-98% -$2.44K ﹤0.01% 2607
2025
Q3 		$2.37K Buy
+726
New +$2.29K ﹤0.01% 2403
2024
Q4 		– Sell
-2,180
Closed -$40.3K – 2173
2024
Q3 		$40.3K Hold
2,180
– – ﹤0.01% 1253
2024
Q2 		$46.9K Buy
2,180
+60
+3% +$1.38K ﹤0.01% 1176
2024
Q1 		$49K Buy
2,120
+280
+15% +$7.95K ﹤0.01% 766
2023
Q4 		$55.1K Sell
1,840
-2,350
-56% -$51.9K ﹤0.01% 715
2023
Q3 		$85.9K Buy
4,190
+1,233
+42% +$22.4K ﹤0.01% 769
2023
Q2 		$58.8K Buy
2,957
+1,117
+61% +$22.6K ﹤0.01% 697
2023
Q1 		$31.5K Buy
+1,840
New +$36K ﹤0.01% 761

Other funds holding RCKT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AC
Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return

Clearstead Advisors's RCKT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Rocket Pharmaceuticals (RCKT) in Q2 2026: 122 shares worth $419. The stake represents ﹤0.01% of the portfolio and ranks #2976 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in RCKT as recently as Q4 2025.

Clearstead Advisors first reported a position in RCKT in Q1 2023 and has held it in 10 quarters since. The position peaked at $85.9K in Q3 2023. 60 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Clearstead Advisors held 122 shares of Rocket Pharmaceuticals worth $419 as of Q2 2026.
  • Rocket Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2976 holding.
  • Clearstead Advisors first reported a position in Rocket Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
  • Clearstead Advisors's Rocket Pharmaceuticals position peaked at $85.9K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.